{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:34:48Z","timestamp":1793896488107,"version":"4.8.0"},"reference-count":32,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,8]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Determining fitness for intensive chemotherapy in an older adult with acute myeloid leukemia (AML) is an unanswered age-old question. Geriatric assessment captures any variation in multidimensional health, which can influence treatment tolerance. A prospective study is necessary to validate fitness criteria, determine whether geriatric assessment\u2013based fitness performs superiorly to other criteria, and what components of geriatric assessment are associated with treatment tolerance. A validation study should enroll diverse patients from both academic and community centers and patients receiving intensive and lower-intensity chemotherapy. Geriatric assessment should include at minimum measures of comorbidity burden, cognition, physical function, and emotional health, which in previous smaller studies have shown to be associated with mortality in AML. These assessments should be completed before or within a few days of initiation of chemotherapy to reduce the influence of chemotherapy on the assessment results. Treatment tolerance has been measured by rates of toxicities in patients with solid malignancies; however, during the\u00a0initial treatment of AML, rates of toxicities are very high\u00a0regardless of treatment intensity. Early mortality, frequently used in previous studies, can provide a highly consequential and easily identifiable measure of treatment tolerance. The key end point to assess treatment tolerance, thus, should include early mortality. Other end points may include decline in function and quality of life and treatment modifications or cessation due to toxicities. Validating fitness criteria can guide treatment selection and supportive care interventions and are crucial to guide fitness-based trial eligibility, inform the interpretation of trial results, and facilitate drug labeling.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023022611","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T22:01:52Z","timestamp":1701727312000},"page":"483-487","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":31,"title":["Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2513-0533","authenticated-orcid":false,"given":"Vijaya Raj","family":"Bhatt","sequence":"first","affiliation":[{"name":"1Fred & Pamela Buffett Cancer Center, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7809-0996","authenticated-orcid":false,"given":"Geoffrey L.","family":"Uy","sequence":"additional","affiliation":[{"name":"2Division of Oncology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6262-1123","authenticated-orcid":false,"given":"Heidi D.","family":"Klepin","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest University Health System, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"23","key":"2024020816242193700_bib1","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1182\/blood.2019001299","article-title":"Ready for prime time: role for geriatric assessment to improve quality of care in hematology practice","volume":"134","author":"Klepin","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2024020816242193700_bib2","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1182\/blood.2021015200","article-title":"Toward consensus on geriatric assessment in AML","volume":"139","author":"Klepin","year":"2022","journal-title":"Blood"},{"issue":"21","key":"2024020816242193700_bib3","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1182\/blood-2012-12-471680","article-title":"Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia","volume":"121","author":"Klepin","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2024020816242193700_bib4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jgo.2019.10.002","article-title":"Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: report of CALGB 361006 (Alliance)","volume":"11","author":"Klepin","year":"2020","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"12","key":"2024020816242193700_bib5","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1182\/bloodadvances.2021006872","article-title":"Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101","volume":"6","author":"Ritchie","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"2024020816242193700_bib6","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jgo.2022.04.005","article-title":"Integrating geriatric assessment and genetic profiling to personalize therapy selection in older adults with acute myeloid leukemia","volume":"13","author":"Bhatt","year":"2022","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"11","key":"2024020816242193700_bib7","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood.2021013671","article-title":"Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML","volume":"139","author":"Min","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2024020816242193700_bib8","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/leu.2012.303","article-title":"Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO Group on a new tool for therapy decision making","volume":"27","author":"Ferrara","year":"2013","journal-title":"Leukemia"},{"issue":"33","key":"2024020816242193700_bib9","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1200\/JCO.2011.35.7525","article-title":"Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment","volume":"29","author":"Walter","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"35","key":"2024020816242193700_bib10","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1200\/JCO.20.01392","article-title":"Accuracy of SIE\/SIES\/GITMO Consensus criteria for unfitness to predict early mortality after intensive chemotherapy in adults with AML or other high-grade myeloid neoplasm","volume":"38","author":"Palmieri","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2024020816242193700_bib11","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1038\/s41375-022-01677-z","article-title":"Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia\u2014a Grand Ouest Against Leukemia (GOAL) study","volume":"36","author":"Desprez","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"2024020816242193700_bib12","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jamaoncol.2017.2714","article-title":"Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality","volume":"3","author":"Sorror","year":"2017","journal-title":"JAMA Oncol"},{"issue":"9757","key":"2024020816242193700_bib13","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/S0140-6736(10)62105-8","article-title":"Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes","volume":"376","author":"Krug","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"2024020816242193700_bib14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajh.26395","article-title":"Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy","volume":"97","author":"Sasaki","year":"2022","journal-title":"Am J Hematol"},{"issue":"7","key":"2024020816242193700_bib15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-022-00700-x","article-title":"A\u00a0scoring\u00a0system for AML patients aged 70\u00a0years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries","volume":"12","author":"B\u00e9rard","year":"2022","journal-title":"Blood Cancer J"},{"issue":"25","key":"2024020816242193700_bib16","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"2024020816242193700_bib17","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1200\/JCO.2015.65.4327","article-title":"Validation of a prediction tool for chemotherapy toxicity in older adults with cancer","volume":"34","author":"Hurria","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"2024020816242193700_bib18","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"10314","key":"2024020816242193700_bib19","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","article-title":"Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study","volume":"398","author":"Mohile","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"2024020816242193700_bib20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/jamaoncol.2019.4728","article-title":"Communication with older patients with cancer using geriatric assessment: a cluster-randomized clinical trial from the National Cancer Institute Community Oncology Research Program","volume":"6","author":"Mohile","year":"2020","journal-title":"JAMA Oncol"},{"issue":"11","key":"2024020816242193700_bib21","doi-asserted-by":"crossref","first-page":"e214158","DOI":"10.1001\/jamaoncol.2021.4158","article-title":"Geriatric assessment-driven intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial","volume":"7","author":"Li","year":"2021","journal-title":"JAMA Oncol"},{"issue":"6","key":"2024020816242193700_bib22","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/jamaoncol.2021.0848","article-title":"Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer: the GO2 Phase 3 Randomized Clinical Trial","volume":"7","author":"Hall","year":"2021","journal-title":"JAMA Oncol"},{"issue":"60","key":"2024020816242193700_bib23","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jncimonographs\/lgac021","article-title":"Integrating geriatric assessment measures into National Cancer Institute Clinical Trials","volume":"2022","author":"Magnuson","year":"2022","journal-title":"J\u00a0Natl Cancer Inst Monogr"},{"issue":"2","key":"2024020816242193700_bib24","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3324\/haematol.2012.067892","article-title":"Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome","volume":"98","author":"Deschler","year":"2013","journal-title":"Haematologica"},{"issue":"23","key":"2024020816242193700_bib25","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood.2020005498","article-title":"Geriatric assessment and survival among older adults receiving postremission therapy for acute myeloid leukemia","volume":"136","author":"Saad","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2024020816242193700_bib26","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2141.2009.07663.x","article-title":"Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials","volume":"145","author":"Wheatley","year":"2009","journal-title":"Br J Haematol"},{"issue":"7","key":"2024020816242193700_bib27","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2024020816242193700_bib28","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/jgs.14301","article-title":"Effect of intensive chemotherapy on physical, cognitive, and emotional health of\u00a0older adults with acute myeloid leukemia","volume":"64","author":"Klepin","year":"2016","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"1","key":"2024020816242193700_bib29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jgo.2019.02.002","article-title":"Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes","volume":"11","author":"Molga","year":"2020","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"5","key":"2024020816242193700_bib30","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1158\/1055-9965.EPI-19-1277","article-title":"Age at diagnosis and patient preferences for treatment outcomes in AML: a discrete choice experiment to explore meaningful benefits","volume":"29","author":"Richardson","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"2024020816242193700_bib31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/fon-2021-0260","article-title":"Preferences of adults with cancer for systemic cancer treatment: do preferences differ based on age?","volume":"18","author":"Dhakal","year":"2022","journal-title":"Future Oncol"},{"issue":"4","key":"2024020816242193700_bib32","first-page":"1006","article-title":"Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens","volume":"108","author":"Jensen","year":"2023","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2023022611\/2211227\/blood_bld-2023-022611-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2023022611\/2211227\/blood_bld-2023-022611-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T16:25:30Z","timestamp":1707409530000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/6\/483\/506502\/Determining-treatment-tolerance-and-fitness-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,2,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023022611","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]}}}